Amlodipine and Landmark Trials: A Review

High blood pressure is considered one of the major risk factors for heart disease. In addition to evidence low disease and death with adequate control pressure, antihypertensive treatment still less effective in clinical practice. It well documented that there a decrease cardiovascular events, such as stroke MI, potent therapies combat high pressure. This, however, generally believed be result phase. This review paper includes focuses on from trials support amlodipine first-line anti-hypertensive agent, showing how its unique properties can provide better protection compared other agents prevent Evidence many randomized controlled presented below shows has excellent efficacy safety, first-rate agent not only BP but also safely improve patient outcomes. Patients treated this drug have benefited they fewer hospitals lower rates recovery. Its mechanism action leads reduction development atherosclerosis. addition, 24 hours may helpful an adjunct patients renal impairment by reducing progression end-stage